HPV-Specific CD8+ T-Cell Detection for Oral Lichen Planus Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools to diagnose and treat severe erosive oral lichen planus (OLP), a chronic inflammatory disease characterized by dysregulated cytotoxic T-cell responses, with the role of human papillomavirus (HPV) in its pathogenesis remaining unclear due to the absence of accurate diagnostic and therapeutic approaches.
Innovation Solution
The development of methods and compositions for diagnosing and treating OLP involves detecting HPV presence or immune responses using HPV peptides, specific primers, and TCRVβ3 sequencing, followed by treatment with anti-HPV drugs like cidofovir, and potentially combining with steroid treatments or extracorporeal photochemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for OLP, then general inflammatory markers can be detected, but specific HPV-related immune responses cannot be accurately identified
Solution Approach 1:
The patent uses HPV peptides as intermediaries to bridge the detection between T-cells and HPV antigens. These peptides serve as specific mediators that enable the detection system to identify HPV-specific immune responses without requiring direct access to viral antigens or complex in vivo assays.
Solution Approach 2:
The patent replaces complex mechanical/invasive diagnostic procedures with molecular biology techniques. Instead of relying on clinical observation or general inflammatory markers, the invention uses PCR, sequencing, and peptide-based assays to detect specific molecular signatures of HPV-related OLP.
2Object-affected harmful factors
If immunomodulatory systemic therapies are used to treat OLP, then inflammation can be suppressed, but the underlying HPV infection and specific immune dysregulation are not addressed
Solution Approach 1:
The patent extracts and targets the specific pathogenic component (HPV infection) from the general inflammatory process. By identifying and treating the HPV-specific immune response separately from general inflammation, the therapy addresses the root cause rather than just suppressing symptoms.
Solution Approach 2:
The patent performs preliminary identification of HPV-specific T-cell responses before initiating targeted therapy. This preliminary diagnostic action allows for personalized treatment planning and ensures that the subsequent therapy is directed at the correct pathogenic mechanism.
3Loss of information
If the role of HPV in OLP pathogenesis is investigated using current methods, then general viral presence can be detected, but specific immune responses against HPV cannot be characterized
Solution Approach 1:
The patent segments the immune response analysis into distinct components: HPV peptide recognition, TCRVβ3 sequencing, and clonal expansion analysis. This segmentation allows each aspect to be measured independently with appropriate precision while maintaining overall system manageability.
Solution Approach 2:
The patent creates a multi-functional diagnostic platform that can simultaneously detect HPV DNA, characterize T-cell responses, sequence TCR variants, and quantify clonal expansions using a coordinated set of methods. This universal approach replaces multiple separate assays with an integrated system.
Data Source
Figure 1a~1d
Figure 2a~2c
Figure 3a~3e
AI summary
A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.